Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | HRH2 | P25021 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1332067 | 0.91 | HTR1A (0.62) | HTR1ASLC6A4KCNH2ABCB1 | |
| SCHEMBL1332723 | 0.89 | HTR1A (0.58) | HTR1ASLC6A4KCNH2ABCB1DRD2 | |
| SCHEMBL3842761 | 0.88 | KCNH2 (0.47) | HTR1ASLC6A4KCNH2ABCB1HRH2 | |
| SCHEMBL1334166 | 0.88 | HTR1A (0.57) | HTR1ASLC6A4KCNH2ABCB1DRD2 | |
| SCHEMBL1333139 | 0.88 | HTR1A (0.57) | HTR1ASLC6A4KCNH2ABCB1 | |
| SCHEMBL1332075 | 0.87 | ABCB1 (0.61) | HTR1ASLC6A4KCNH2ABCB1DRD2 | |
| SCHEMBL1333264 | 0.87 | KCNJ1 (0.55) | KCNH2HRH3 | |
| Hydrochloric Acid SCHEMBL1334285 | 0.86 | KCNJ1 (0.53) | KCNH2 | |
| SCHEMBL1332768 | 0.86 | HTR1A (0.55) | HTR1ASLC6A4KCNH2ABCB1DRD2 | |
| SCHEMBL1332758 | 0.86 | HTR1A (0.55) | HTR1ASLC6A4KCNH2ABCB1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281890-A1 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION | 2011-11-17 | — | — | US | claimed |
| US-8183374-B2 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION (JP) | 2012-05-22 | — | — | US | disclosed |
| US-20110281890-A1 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION | 2011-11-17 | — | — | US | disclosed |
| EP-2340835-A1 | Piperidine and piperazine derivatives | M's Science Corporation (JP) | 2011-07-06 | — | — | EP | disclosed |
| EP-1976525-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MS SCIENCE CORP (JP) | 2010-11-03 | — | — | EP | disclosed |
| US-20100256162-A1 | Piperazine and Piperidine Derivatives | AGY THERAPEUTICS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100137334-A1 | Piperidine and Piperazine Derivatives | SUN CONNIE L | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137334-A1 | Piperidine and Piperazine Derivatives | SIGMAR1, OPRM1, OPRD1 | HTR1A 23/4885SLC6A4 424/4885KCNH2 332/4885 |
| US-20110281890-A1 | Piperidine and piperazine derivatives | SIGMAR1, OPRM1, OPRD1 | HTR1A 49/4885SLC6A4 488/4885KCNH2 369/4885 |
| US-20100256162-A1 | Piperazine and Piperidine Derivatives | SIGMAR1, OPRM1, OPRD1 | HTR1A 50/4885SLC6A4 497/4885KCNH2 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.